Cited by 501CRISPR and Genetic EngineeringRNA Interference and Gene DeliveryRNA regulation and disease

The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.

Structure-guided chemical modification of guide RNA enables potent non-viral in vivo genome editing

Open access

Yin, Hao, Song, Chun-Qing, Suresh, Sneha, Wu, Qiongqiong, Walsh, Stephen, Rhym, Luke Hyunsik, Mintzer, Esther, Bolukbasi, Mehmet Fatih, Zhu, Lihua Julie, Kauffman, Kevin, Mou, Haiwei, Oberholzer, Alicia, Ding, Junmei, Kwan, Suet-Yan, Bogorad, Roman L, Zatsepin, Timofei, Koteliansky, Victor, Wolfe, Scot A, Xue, Wen, Langer, Robert, Anderson, Daniel G·2017·Nature Biotechnology

DOI 10.1038/nbt.4005PMC PMC5901668

Open this paper in CoChat — free account

Abstract

Efficient genome editing with Cas9-sgRNA in vivo has required the use of viral delivery systems, which have limitations for clinical applications. Translational efforts to develop other RNA therapeutics have shown that judicious chemical modification of RNAs can improve therapeutic efficacy by reducing susceptibility to nuclease degradation. Guided by the structure of the Cas9-sgRNA complex, we identify regions of sgRNA that can be modified while maintaining or enhancing genome-editing activity, and we develop an optimal set of chemical modifications for in vivo applications. Using lipid nanoparticle formulations of these enhanced sgRNAs (e-sgRNA) and mRNA encoding Cas9, we show that a single intravenous injection into mice induces >80% editing of Pcsk9 in the liver. Serum Pcsk9 is reduced to undetectable levels, and cholesterol levels are significantly lowered about 35% to 40% in animals. This strategy may enable non-viral, Cas9-based genome editing in the liver in clinical settings.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/nbt.4005

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
The new frontier of genome engineering with CRISPR-Cas9
Doudna, J. A., & Charpentier, E. (2014) · Science · doi:10.1126/science.1258096 · Cited by 7,062
Cpf1 Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas System
Zetsche, B., Gootenberg, J. S., Abudayyeh, O. O., Slaymaker, I. M., Makarova, K. S., Essletzbichler, P., Volz, S. E., Joung, J., van der Oost, J., Regev, A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.09.038 · Cited by 4,761
CRISPR-Mediated Modular RNA-Guided Regulation of Transcription in Eukaryotes
Gilbert, L. A., Larson, M. H., Morsut, L., Liu, Z., Brar, G. A., Torres, S. E., Stern-Ginossar, N., Brandman, O., Whitehead, E. H., Doudna, J. A., et al. (2013) · Cell · doi:10.1016/j.cell.2013.06.044 · Cited by 3,696
High-Frequency off-Target Mutagenesis Induced by CRISPR-Cas Nucleases in Human Cells
Fu, Y., Foden, J. A., Khayter, C., Maeder, M. L., Reyon, D., Joung, J. K., & Sander, J. D. (2013) · Nature Biotechnology · doi:10.1038/nbt.2623 · Cited by 3,292
Non-viral vectors for gene-based therapy
Yin, H., Kanasty, R. L., Eltoukhy, A. A., Vegas, A. J., Dorkin, J. R., & Anderson, D. G. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3763 · Cited by 3,123
Self-citation
In vivo genome editing using Staphylococcus aureus Cas9
Ran, F. A., Cong, L., Yan, W. X., Scott, D. A., Gootenberg, J. S., Kriz, A. J., Zetsche, B., Shalem, O., Wu, X., Makarova, K. S., et al. (2015) · Nature · doi:10.1038/nature14299 · Cited by 2,687
Easy quantitative assessment of genome editing by sequence trace decomposition
Brinkman, E. K., Chen, T., Amendola, M., & van Steensel, B. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku936 · Cited by 2,390

Flagged first, then by citations

Show all 48 references

Sorted by citations

Items 201–300 of 501

Tutorial: design and execution of CRISPR in vivo screens
Braun, C. J., Adames, A. C., Saur, D., & Rad, R. (2022) · Nature Protocols · doi:10.1038/s41596-022-00700-y · Cited by 38
Improved Cas9 activity by specific modifications of the tracrRNA
Scott, T. A., Urak, R. Z., Soemardy, C., & Morris, K. V. (2019) · Scientific Reports · doi:10.1038/s41598-019-52616-5 · Cited by 35
Emerging Gene Therapeutics for Epidermolysis Bullosa under Development
Bischof, J., Hierl, M., & Koller, U. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25042243 · Cited by 36
RNA lipid nanoparticles as efficient in vivo CRISPR-Cas9 gene editing tool for therapeutic target validation in glioblastoma cancer stem cells
Rouatbi, N., Walters, A. A., Costa, P. M., Qin, Y., Liam‐Or, R., Grant, V., Pollard, S. M., Wang, J. T.-W., & Al‐Jamal, K. T. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.09.019 · Cited by 36
Rapid generation of long, chemically modified pegRNAs for prime editing
Lei, X., Huang, A., Chen, D., Wang, X., Ji, R.-J., Wang, J., Zhang, Y., Zhang, Y., Lu, S., Zhang, K., et al. (2024) · Nature Biotechnology · doi:10.1038/s41587-024-02394-x · Cited by 31
Self-citation
Synthetic Vehicles for Encapsulation and Delivery of CRISPR/Cas9 Gene Editing Machinery
Carboni, V., Maaliki, C., Alyami, M., Alsaiari, S. K., & Khashab, N. M. (2019) · Advanced Therapeutics · doi:10.1002/adtp.201800085 · Cited by 34
Engineering CRISPR mouse models of cancer
Weber, J., & Rad, R. (2019) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2019.04.001 · Cited by 33
Engineering Cas9 for human genome editing
Slaymaker, I. M., & Gaudelli, N. M. (2021) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2021.03.004 · Cited by 34
Gene editing for dyslipidemias: New tools to “cut” lipids
Stankov, S. G., & Cuchel, M. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.01.010 · Cited by 34
Genome and base editing for genetic hearing loss
Niggemann, P., György, B., & Chen, Z. (2020) · Hearing Research · doi:10.1016/j.heares.2020.107958 · Cited by 32
Programming PAM antennae for efficient CRISPR-Cas9 DNA editing
Wang, F., Hao, Y., Li, Q., Li, J., Zhang, H., Zhang, X., Wang, L., Bustamante, C., & Fan, C. (2020) · Science Advances · doi:10.1126/sciadv.aay9948 · Cited by 33
Strategies for Enhancing the Homology-Directed Repair Efficiency of CRISPR-Cas Systems
Sun, W., Liu, H., Yin, W., Qiao, J., Zhao, X., & Liu, Y. (2022) · The CRISPR Journal · doi:10.1089/crispr.2021.0039 · Cited by 33
Pre-clinical non-viral vectors exploited for in vivo CRISPR/Cas9 gene editing: an overview
Rouatbi, N., McGlynn, T., & Al‐Jamal, K. T. (2022) · Biomaterials Science · doi:10.1039/d1bm01452h · Cited by 33
In utero delivery of mRNA to the heart, diaphragm and muscle with lipid nanoparticles
Gao, K., Li, J., Song, H., Han, H., Wang, Y., Yin, B., Farmer, D. L., Murthy, N., & Wang, A. (2023) · Bioactive Materials · doi:10.1016/j.bioactmat.2023.02.011 · Cited by 33
Enrichment strategies to enhance genome editing
Mikkelsen, N. S., & Bak, R. O. (2023) · Journal of Biomedical Science · doi:10.1186/s12929-023-00943-1 · Cited by 32
Efficient CRISPR/Cas9-Mediated Gene Knockin in Mouse Hematopoietic Stem and Progenitor Cells
Tran, N. T., Sommermann, T. G., Graf, R., Trombke, J., Pempe, J., Petsch, K., Kühn, R., Rajewsky, K., & Chu, V. T. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.08.065 · Cited by 34
Modulating CRISPR/Cas9 genome-editing activity by small molecules
Chen, S., Chen, D., Liu, B., & Haisma, H. J. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.11.018 · Cited by 32
Biomaterial-Based CRISPR/Cas9 Delivery Systems for Tumor Treatment
Li, M., Chen, F., Yang, Q., Tang, Q., Xiao, Z., Tong, X., Zhang, Y., Lei, L., & Li, S. (2024) · Biomaterials Research · doi:10.34133/bmr.0023 · Cited by 32
Controlling CRISPR‐Cas9 by guide RNA engineering
Hu, L., Li, Y., Wang, J., Zhao, Y., & Wang, Y. (2022) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1731 · Cited by 31
Phosphonoacetate Modifications Enhance the Stability and Editing Yields of Guide RNAs for Cas9 Editors
Ryan, D. E., Diamant-Levi, T., Steinfeld, I., Taussig, D., Visal-Shah, S., Thakker, S., Lunstad, B. D., Kaiser, R. J., McCaffrey, R. M., Ortiz, M., et al. (2022) · Biochemistry · doi:10.1021/acs.biochem.1c00768 · Cited by 30
Lipid-nanoparticle-enabled nucleic acid therapeutics for liver disorders
Arjunan, P., Kathirvelu, D., Mahalingam, G., Goel, A., Zacharaiah, U. G., Srivastava, A., & Marepally, S. K. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.04.015 · Cited by 33
The evolution and history of gene editing technologies
Randhawa, S., & Sengar, S. (2021) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2021.01.002 · Cited by 31
Improving Stability and Specificity of CRISPR/Cas9 System by Selective Modification of Guide RNAs with 2′-fluoro and Locked Nucleic Acid Nucleotides
Sakovina, L., Vokhtantsev, I. P., Vorobyeva, M., Vorobjev, P., & Новопашина, Д. С. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113460 · Cited by 29
CRISPR/Cas based gene editing: marking a new era in medical science
Prasad, K. M., George, A., Ravi, N. S., & Mohankumar, K. M. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06479-7 · Cited by 27
CRISPR and cardiovascular diseases
Musunuru, K. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac048 · Cited by 36
CRISPR/Cas9-Mediated Treatment Ameliorates the Phenotype of the Epidermolytic Palmoplantar Keratoderma-like Mouse
Luan, X., Chen, X., Tang, Y., Zhang, J., Gao, X., Ke, H., Lin, Z., & Zhang, X. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.05.005 · Cited by 28
Engineering guide RNA to reduce the off-target effects of CRISPR
Wu, J., & Yin, H. (2019) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2019.11.003 · Cited by 28
Self-citation
CrRNA Conformation-Engineered CRISPR-Cas12a System for Robust and Ultrasensitive Nucleic Acid Detection
Li, Y., Hu, Q., Bai, M., Qing, M., & Bai, L. (2025) · Analytical Chemistry · doi:10.1021/acs.analchem.4c06107 · Cited by 29
Characterization of Impurities in Therapeutic RNAs at the Single Nucleotide Level
Goyon, A., Nguyen, D. N., Boulanouar, S., Yehl, P., & Zhang, K. (2022) · Analytical Chemistry · doi:10.1021/acs.analchem.2c04681 · Cited by 26
Intelligent Design of Lipid Nanoparticles for Enhanced Gene Therapeutics
Yuan, Y., Li, Y., Li, G., Lei, L., Huang, X., Li, M., & Yao, Y. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00925 · Cited by 28
Therapeutic applications of CRISPR /Cas9 gene editing technology for the treatment of ocular diseases
Sundaresan, Y., Yacoub, S., Kodati, B., Amankwa, C. E., Raola, A., & Zode, G. S. (2023) · FEBS Journal · doi:10.1111/febs.16771 · Cited by 27
Recent advances in therapeutic CRISPR-Cas9 genome editing: mechanisms and applications
Zhou, L., & Yao, S. (2023) · Molecular Biomedicine · doi:10.1186/s43556-023-00115-5 · Cited by 29
Innovations in CRISPR technology
Brooks, A. K., & Gaj, T. (2018) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2018.03.007 · Cited by 26
Engineering the Direct Repeat Sequence of crRNA for Optimization of FnCpf1-Mediated Genome Editing in Human Cells
Li, L., He, X., Zhao, T., Gu, L., Liu, Y., Liu, X., Liu, H., Yang, F., Tu, M., Tang, L., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.08.021 · Cited by 25
CRISPR somatic genome engineering and cancer modeling in the mouse pancreas and liver
Kaltenbacher, T., Löprich, J., Maresch, R., Weber, J., Müller, S., Oellinger, R., Groß, N., Griger, J., Krätzig, N. D. A., Avramopoulos, P., et al. (2022) · Nature Protocols · doi:10.1038/s41596-021-00677-0 · Cited by 25
Nonviral Delivery of CRISPR/Cas Systems in mRNA Format
Liu, Z., Li, Z., & Li, B. (2022) · Advanced NanoBiomed Research · doi:10.1002/anbr.202200082 · Cited by 25
Gene editing innovations and their applications in cardiomyopathy research
Kyriakopoulou, E., Monnikhof, T., & van Rooij, E. (2023) · Disease Models & Mechanisms · doi:10.1242/dmm.050088 · Cited by 26
Toward Understanding in Vivo Sequestration of Nanoparticles at the Molecular Level
Yin, B., Li, K. H. K., Ho, L. W. C., Chan, C. K. W., & Choi, C. H. J. (2018) · ACS Nano · doi:10.1021/acsnano.8b00141 · Cited by 24
New Technologies and the Law in War and Peace
(2018) · Cambridge University Press eBooks · doi:10.1017/9781108609388 · Cited by 24
In vivo LNP-CRISPR Approaches for the Treatment of Hemophilia
Lee, J. H., & Han, J. P. (2024) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-024-00705-1 · Cited by 24
CRISPR/Cas9-mediated correction of mutated copper transporter ATP7B
Pöhler, M., Guttmann, S., Nadzemova, O., Lenders, M., Brand, E., Zibert, A., Schmidt, H., & Sandfort, V. (2020) · PLoS ONE · doi:10.1371/journal.pone.0239411 · Cited by 29
PEG-OligoRNA Hybridization of mRNA for Developing Sterically Stable Lipid Nanoparticles toward In Vivo Administration
Kurimoto, S., Yoshinaga, N., Igarashi, K., Matsumoto, Y., Cabral, H., & Uchida, S. (2019) · Molecules · doi:10.3390/molecules24071303 · Cited by 23
CRISPR/Cas9 gene editing: a novel strategy for fighting drug resistance in respiratory disorders
Hussen, B. M., Najmadden, Z. B., Abdullah, S. R., Rasul, M. F., Mustafa, S. A., Ghafouri‐Fard, S., & Taheri, M. N. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01713-8 · Cited by 28
Modification of Cas9, gRNA and PAM: Key to further regulate genome editing and its applications
Gupta, R. K., Gupta, D., Kazi, T. A., Dey, D., Singh, R., Swarnakar, S., Ravichandiran, V., Roy, S., & Ghosh, D. (2021) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2020.12.001 · Cited by 23
CES1‐Triggered Liver‐Specific Cargo Release of CRISPR/Cas9 Elements by Cationic Triadic Copolymeric Nanoparticles Targeting Gene Editing of PCSK9 for Hyperlipidemia Amelioration
Zhao, Y., Li, Y., Wang, F., Gan, X., Zheng, T., Chen, M., Li, W., Chen, J., & Yu, C. (2023) · Advanced Science · doi:10.1002/advs.202300502 · Cited by 22
Lipo-Xenopeptide Polyplexes for CRISPR/Cas9 based Gene editing at ultra-low dose
Germer, J., Lessl, A.-L., Pöhmerer, J., Grau, M., Weidinger, E., Höhn, M., Yazdi, M., Cappelluti, M. A., Lombardo, A., Lächelt, U., et al. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.04.037 · Cited by 25
Polyrotaxane Nanocarriers Can Deliver CRISPR/Cas9 Plasmid to Dystrophic Muscle Cells to Successfully Edit the DMD Gene
Emami, M. R., Young, C. S., Ji, Y. C., Liu, X., Mokhonova, E. I., Pyle, A. D., Meng, H., & Spencer, M. J. (2019) · Advanced Therapeutics · doi:10.1002/adtp.201900061 · Cited by 22
Multivalent Peptide-Functionalized Bioreducible Polymers for Cellular Delivery of Various RNAs
Yang, D., Eldredge, A. C., Hickey, J. C., Muradyan, H., & Guan, Z. (2020) · Biomacromolecules · doi:10.1021/acs.biomac.0c00211 · Cited by 22
Highly efficient and safe genome editing by CRISPR-Cas12a using CRISPR RNA with a ribosyl-2′-O-methylated uridinylate-rich 3′-overhang in mouse zygotes
Ha, D.-I., Lee, J. M., Lee, N., Kim, D., Ko, J., & Kim, Y.-S. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-00521-7 · Cited by 23
Lipid‐based nucleic acid therapeutics with in vivo efficacy
Sufian, M. A., & Ilies, M. A. (2022) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1856 · Cited by 23
Targeting Fusobacterium nucleatum through chemical modifications of host-derived transfer RNA fragments
Yang, M., Dong, P., Cen, L., Shi, W., He, X., & Li, J. (2023) · The ISME Journal · doi:10.1038/s41396-023-01398-w · Cited by 22
Barcoding chemical modifications into nucleic acids improves drug stability in vivo
Sago, C. D., Kalathoor, S., Fitzgerald, J. P., Lando, G. N., Djeddar, N., Bryksin, A. V., & Dahlman, J. E. (2018) · Journal of Materials Chemistry B · doi:10.1039/c8tb01642a · Cited by 23
Engineering nucleic acid chemistry for precise and controllable CRISPR/Cas9 genome editing
Cai, W., & Wang, M. (2019) · 中国科学通报：英文版 · doi:10.1016/j.scib.2019.07.035 · Cited by 21
Expanding the Potential of Mammalian Genome Engineering via Targeted DNA Integration
Zhang, M., Yang, C., Tasan, I., & Zhao, H. (2021) · ACS Synthetic Biology · doi:10.1021/acssynbio.0c00576 · Cited by 20
Optical Control of a CRISPR/Cas9 System for Gene Editing by Using Photolabile crRNA
Zhang, Y., Ling, X., Su, X., Zhang, S., Wang, J., Zhang, P., Feng, W., Zhu, Y. Y., Liu, T., & Tang, X. (2020) · Angewandte Chemie · doi:10.1002/ange.202009890 · Cited by 21
Versatile modification of the CRISPR/Cas9 ribonucleoprotein system to facilitate in vivo application
Sun, B., Chen, H., & Gao, X. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.08.007 · Cited by 20
The Potential of Nanomedicine to Unlock the Limitless Applications of mRNA
Taina-González, L., & de la Fuente, M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14020460 · Cited by 23
Spacer Fidelity Assessments of Guide RNA by Top-Down Mass Spectrometry
Macias, L. A., Garcia, S. P., Back, K. M., Wu, Y., Johnson, G. H., Kathiresan, S., Bellinger, A. M., Rohde, E., Freitas, M. A., & Madsen, J. A. (2023) · ACS Central Science · doi:10.1021/acscentsci.3c00289 · Cited by 20
A review of RNA nanoparticles for drug/gene/protein delivery in advanced therapies: Current state and future prospects
Vosoughi, P., Naghib, S. M., Kangarshahi, B. M., & Mozafari, M. R. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.139532 · Cited by 23
Functional Genomics in Pancreatic β Cells: Recent Advances in Gene Deletion and Genome Editing Technologies for Diabetes Research
Hu, M., Cherkaoui, I., Misra, S., & Rutter, G. A. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.576632 · Cited by 24
Emerging lipid–polymer hybrid nanoparticles for genome editing
Gameiro, M. D., Mano, J. F., & Gaspar, V. M. (2024) · Polymer Chemistry · doi:10.1039/d4py00298a · Cited by 22
Making gene editing a therapeutic reality
Conboy, I. M., Murthy, N., Etienne, J., & Robinson, Z. R. (2018) · F1000Research · doi:10.12688/f1000research.16106.1 · Cited by 19
Editing out HIV: application of gene editing technology to achieve functional cure
Xun, J., Zhang, X., Guo, S., Lu, H., & Chen, J. (2021) · Retrovirology · doi:10.1186/s12977-021-00581-1 · Cited by 22
Current knowledge on the tissue distribution of mRNA nanocarriers for therapeutic protein expression
Zadory, M., Lopez, E., Babity, S., Gravel, S., & Brambilla, D. (2022) · Biomaterials Science · doi:10.1039/d2bm00859a · Cited by 18
CRISPR-Cas9 recognition of enzymatically synthesized base-modified nucleic acids
Yang, H., Eremeeva, E., Abramov, M., Jacquemyn, M., Groaz, E., Daelemans, D., & Herdewijn, P. A. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkac1147 · Cited by 19
Reversal of hepatic fibrosis by the co-delivery of drug and ribonucleoprotein-based genome editor
Gu, J., Sun, J., Tian, K. V., Bian, J., Peng, J., Xu, S. Q., & Zhao, L. (2023) · Biomaterials · doi:10.1016/j.biomaterials.2023.122133 · Cited by 20
Self-delivering, chemically modified CRISPR RNAs for AAV co-delivery and genome editing in vivo
Zhang, H., Kelly, K. L., Lee, J. L. C., Echeverria, D., Cooper, D., Panwala, R., Amrani, N., Chen, Z., Gaston, N., Wagh, A. A., et al. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad1125 · Cited by 19
Self-citation
CRISPR and transposon in vivo screens for cancer drivers and therapeutic targets
Noorani, I., Bradley, A., & Rosa, J. D. L. (2020) · Genome biology · doi:10.1186/s13059-020-02118-9 · Cited by 20
Aptamer-based cell-free detection system to detect target protein
Chen, J., Zhuang, X., Zheng, J., Yang, R., Wu, F., Zhang, A., & Fang, B. (2021) · Synthetic and Systems Biotechnology · doi:10.1016/j.synbio.2021.07.004 · Cited by 18
In vivo genome editing using 244-cis LNPs and low-dose AAV achieves therapeutic threshold in hemophilia A mice
Han, J. P., Lee, Y., Lee, J. H., Chung, H. Y., Lee, G. S., Nam, Y. R., Choi, M., Moon, K., Lee, H., Lee, H., et al. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.102050 · Cited by 19
In vitro Generation of CRISPR-Cas9 Complexes with Covalently Bound Repair Templates for Genome Editing in Mammalian Cells
Savić, N., Ringnalda, F. C. A. S., Berk, C., Bargsten, K., Hall, J., Jínek, M., & Schwank, G. (2019) · BIO-PROTOCOL · doi:10.21769/bioprotoc.3136 · Cited by 18
In vivo liver targeted genome editing as therapeutic approach: progresses and challenges
Simoni, C., Barbon, E., Muro, A. F., & Cantore, A. (2024) · Frontiers in Genome Editing · doi:10.3389/fgeed.2024.1458037 · Cited by 20
Immune evasive DNA donors and recombinases license kilobase-scale writing
Tou, C. J., Xie, K., da Silva, J. F., Kalailingam, P., Amar‐Lewis, E., Rufino‐Ramos, D., Sawyer, W., Eller, M. L., Starzyk, J., Majumdar, I. D., et al. (2026) · Nature · doi:10.1038/s41586-026-10241-z · Cited by 19
Introduction and History of the Chemistry of Nucleic Acids Therapeutics
Gait, M. J., & Agrawal, S. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2010-6_1 · Cited by 18
Development of New Genome Editing Tools for the Treatment of Hyperlipidemia
Preta, G. (2023) · Cells · doi:10.3390/cells12202466 · Cited by 19
Genome editing technologies to treat rare liver diseases
Trevisan, M., Masi, G., & Palù, G. (2020) · Translational Gastroenterology and Hepatology · doi:10.21037/tgh.2019.10.10 · Cited by 17
Chemical Modifications in RNA Interference and CRISPR/Cas Genome Editing Reagents
Lennox, K. A., & Behlke, M. A. (2020) · Methods in molecular biology · doi:10.1007/978-1-0716-0290-4_2 · Cited by 17
Xeno Nucleic Acids as Functional Materials: From Biophysical Properties to Application
Bian, T., Pei, Y., Gao, S., Zhou, S., Sun, X., Dong, M., & Song, J. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202401207 · Cited by 17
Reversible RNA Acylation Using Bio-Orthogonal Chemistry Enables Temporal Control of CRISPR-Cas9 Nuclease Activity
Pandit, B., Fang, L., Kool, E. T., & Royzen, M. (2024) · ACS Chemical Biology · doi:10.1021/acschembio.4c00117 · Cited by 16
Molecular Additives Significantly Enhance Glycopolymer-Mediated Transfection of Large Plasmids and Functional CRISPR-Cas9 Transcription Activation Ex Vivo in Primary Human Fibroblasts and Induced Pluripotent Stem Cells
Boyle, W. S., Twaroski, K., Woska, E. C., Tolar, J., & Reineke, T. M. (2018) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.8b00760 · Cited by 17
Engineering CRISPR-Cas9 RNA–Protein Complexes for Improved Function and Delivery
Rouet, R., de Oñate, L., Li, J., Murthy, N., & Wilson, R. C. (2018) · The CRISPR Journal · doi:10.1089/crispr.2018.0037 · Cited by 16
Liver-directed gene-based therapies for inborn errors of metabolism
Piccolo, P., Rossi, A., & Brunetti‐Pierri, N. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1817375 · Cited by 16
In vivo production of CAR T cell: Opportunities and challenges
Song, Z., Zhou, Y., Wang, B., Geng, Y., Tang, G., Wang, Y., & Yang, J. (2025) · Genes & Diseases · doi:10.1016/j.gendis.2025.101612 · Cited by 17
Applications of Innovation Technologies for Personalized Cancer Medicine: Stem Cells and Gene-Editing Tools
Hasanzadeh, A., Ebadati, A., Dastanpour, L., Aref, A. R., Zangabad, P. S., Kalbasi, A., Dai, X., Mehta, G., Ghasemi, A., Fatahi, Y., et al. (2023) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.3c00102 · Cited by 16
Aspects of Gene Therapy Products Using Current Genome-Editing Technology in Japan
Yamaguchi, T., Uchida, E., Okada, T., Ozawa, K., Onodera, M., Kume, A., Shimada, T., Takahashi, S., Tani, K., Nasu, Y., et al. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.156 · Cited by 16
RNA Engineering for Public Health: Innovations in RNA-Based Diagnostics and Therapeutics
Thavarajah, W., Hertz, L. M., Bushhouse, D. Z., Archuleta, C. M., & Lucks, J. B. (2021) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-101420-014055 · Cited by 15
Viral and nonviral nanocarriers for in vivo CRISPR-based gene editing
Guo, Z., Zhu, A. T., Fang, R. H., & Zhang, L. (2024) · Nano Research · doi:10.1007/s12274-024-6748-5 · Cited by 18
Engineering stimuli-responsive nanocarriers for CRISPR/Cas9 genome editing: next-generation cancer therapeutics
Mehnath, S. (2025) · Journal of Pharmacy and Pharmacology · doi:10.1093/jpp/rgaf127 · Cited by 14
Bio-Orthogonal Chemistry Conjugation Strategy Facilitates Investigation of N-methyladenosine and Thiouridine Guide RNA Modifications on CRISPR Activity
Hoy, A., Zheng, Y. Y., Sheng, J., & Royzen, M. (2022) · The CRISPR Journal · doi:10.1089/crispr.2022.0065 · Cited by 14
Chitosan-based nanoarchitectures for siRNA delivery in cancer therapy: A review of pre-clinical and clinical importance
Bian, X., Yu, X., Lu, S., Jia, L., Li, P., Yin, J., & Tan, S. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.137708 · Cited by 14
Tissue-specific modulation of CRISPR activity by miRNA-sensing guide RNAs
Garcia-Guerra, A., Sathyaprakash, C., de Jong, O. G., Lim, W. F., Vader, P., Andaloussi, S. E., Bath, J., Reiné, J., Aoki, Y., Turberfield, A. J., et al. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkaf016 · Cited by 15
Chemical Modification and Transformation Strategies of Guide RNAs in CRISPR‐Cas9 Gene Editing Systems
Zhang, Y., Wang, Q., Wang, J., & Tang, X. (2021) · ChemPlusChem · doi:10.1002/cplu.202000785 · Cited by 14
Nanoparticles‐Mediated CRISPR/Cas Gene Editing Delivery System
Saw, P. E., Cui, G., & Xu, X. (2022) · ChemMedChem · doi:10.1002/cmdc.202100777 · Cited by 14
Core Hairpin Structure of SpCas9 sgRNA Functions in a Sequence- and Spatial Conformation–Dependent Manner
Jiang, M., Ye, Y., & Li, J. (2020) · SLAS TECHNOLOGY · doi:10.1177/2472630320922813 · Cited by 14
Chitosan-Based Nanocomposites for Biological Applications
Yalçın, S., & Çankaya, N. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.106379 · Cited by 13
siRNA nanoparticle targeting Usp20 lowers lipid levels and ameliorates metabolic syndrome in mice
Ding, Y., Chen, Q., Xu, H., Adi, D., Ding, Y., Luo, W., Zhu, W.-Z., Xu, J.-C., Zhao, X., Shi, X., et al. (2024) · Journal of Lipid Research · doi:10.1016/j.jlr.2024.100626 · Cited by 14
Self-citation
Discovery and engineering of retrons for precise genome editing
Buffington, J., Kuo, H., Hu, K., Chang, Y.-C., Javanmardi, K., Voigt, B., Li, Y.-R., Little, M. E., Devanathan, S. K., Xhemalçe, B., et al. (2025) · Nature Biotechnology · doi:10.1038/s41587-025-02879-3 · Cited by 13
Combination gene therapy for HIV using a conditional suicidal gene with CCR5 knockout
Mehmetoglu-Gurbuz, T., Yeh, R., Garg, H., & Joshi, A. (2021) · Virology Journal · doi:10.1186/s12985-021-01501-7 · Cited by 13
Amide Internucleoside Linkages Are Well Tolerated in Protospacer Adjacent Motif-Distal Region of CRISPR RNAs
Kotikam, V., Gajula, P. K., Coyle, L., & Rozners, E. (2022) · ACS Chemical Biology · doi:10.1021/acschembio.1c00900 · Cited by 13
Natural Nucleoside Modifications in Guide RNAs Can Modulate the Activity of the CRISPR-Cas9 System In Vitro
Prokhorova, D. V., Vokhtantsev, I. P., Tolstova, P. O., Zhuravlev, E. S., Kulishova, L. M., Zharkov, D. O., & Stepanov, G. A. (2022) · The CRISPR Journal · doi:10.1089/crispr.2022.0069 · Cited by 13

Authors: Yin, H., Song, C.-Q., Suresh, S., Wu, Q., Walsh, S., Rhym, L. H., Mintzer, E., Bolukbasi, M. F., Zhu, L. J., Kauffman, K., Mou, H., Oberholzer, A., Ding, J., Kwan, S.-Y., Bogorad, R. L., Zatsepin, T., Koteliansky, V., Wolfe, S. A., Xue, W., Langer, R., & Anderson, D. G.
Affiliations: Koch Institute for Integrative Cancer Research At MIT (US)
University of Massachusetts Chan Medical School (US)
Skolkovo Institute of Science and Technology (RU)
Harvard–MIT Division of Health Sciences and Technology (US)
Corresponding author: Anderson, Daniel G
ORCID: Yin, Hao
Song, Chun-Qing
Suresh, Sneha
Walsh, Stephen
Rhym, Luke Hyunsik
Mintzer, Esther
Bolukbasi, Mehmet Fatih
Zhu, Lihua Julie
Kauffman, Kevin
Mou, Haiwei
Bogorad, Roman L
Zatsepin, Timofei
Wolfe, Scot A
Xue, Wen
Anderson, Daniel G
Venue: Nature Biotechnology
Publisher: Springer Science and Business Media LLC
Published: 2017-11-13
Volume: 35
Issue: 12
Pages: 1179-1187
ISSN: 0733-222X (ISSN-L)
1087-0156
1546-1696
DOI: 10.1038/nbt.4005
PMC: PMC5901668
OpenAlex: W2770127492
Cited by: 499
References: 48
Citations by year: 2026: 39 · 2025: 31 · 2024: 53 · 2023: 63 · 2022: 75 · 2021: 64 · 2020: 52 · 2019: 51 · 2018: 71
FWCI: 19.43
Type: journal article
Language: en
Open access: green
europepmc.org
Licence: www.springer.com/tdm (tdm)
Locations: Nature Biotechnology (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
The Journal of the American Medical Association (JAMA) Network (American Medical Association) (submittedVersion)
DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc)
Funders: Vedecká Grantová Agentúra MŠVVaŠ SR a SAV
Skolkovo Institute of Science and Technology
National Institutes of Health
National Heart, Lung, and Blood Institute (P01HL131471, DP2HL137167)
National Cancer Institute (U54CA151884, R00CA169512, P30CA014051)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA regulation and disease
Keywords: Cas9, in vivo gene editing, non-viral delivery, lipid nanoparticle delivery, PCSK9, cholesterol lowering, RNA therapeutics, nuclease resistance
MeSH terms: Proprotein Convertase 9, Gene Editing, RNA, Guide, CRISPR-Cas Systems, Animals, Liver, Nucleic Acid Conformation, Gene Transfer Techniques, Mice, Nanoparticles, CRISPR-Cas Systems

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Structure-guided chemical modification of guide RNA enables potent non-viral in vivo genome editing

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks